GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aytu BioPharma Inc (STU:AY20) » Definitions » YoY EPS Growth

Aytu BioPharma (STU:AY20) YoY EPS Growth : 100.00% (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Aytu BioPharma YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Aytu BioPharma's YoY EPS Growth for the quarter that ended in Sep. 2024 was 100.00%.

Aytu BioPharma's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was €0.00.

Aytu BioPharma YoY EPS Growth Historical Data

The historical data trend for Aytu BioPharma's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aytu BioPharma YoY EPS Growth Chart

Aytu BioPharma Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 91.32 -8.06 -21.20 93.26 43.67

Aytu BioPharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -390.11 98.18 73.49 -39.82 100.00

Aytu BioPharma YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Aytu BioPharma's YoY EPS Growth for the fiscal year that ended in Jun. 2024 is calculated as:

YoY EPS Growth (A: Jun. 2024 )
=(Earnings per Share (Diluted) (A: Jun. 2024 )-Earnings per Share (Diluted) (A: Jun. 2023 ))/ | Earnings per Share (Diluted) (A: Jun. 2023 ) |
=(-2.657--4.717)/ | -4.717 |
=43.67 %

Aytu BioPharma's YoY EPS Growth for the quarter that ended in Sep. 2024 is calculated as:

YoY EPS Growth (Q: Sep. 2024 )
=(Earnings per Share (Diluted) (Q: Sep. 2024 )-Earnings per Share (Diluted) (Q: Sep. 2023 )) / | Earnings per Share (Diluted) (Q: Sep. 2023 )) |
=(0--1.387)/ | -1.387 |
=100.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aytu BioPharma YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Aytu BioPharma's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Aytu BioPharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aytu BioPharma Inc (STU:AY20) » Definitions » YoY EPS Growth
Comparable Companies
TLPH BFRI BIOE BGXX MSTH HYEX LIFD EVOK CBIH CVSI ZTS XTER:MRK NSE:SUNPHARMA LSE:HLN TSE:4502 XSWX:GALD XTAE:TEVA NSE:DIVISLAB XSWX:SDZ VTRS
Traded in Other Exchanges
AYTU:USA 0A8M:UK
Address
7900 East Union Avenue, Suite 920, Denver, CO, USA, 80237
Website
https://www.aytubio.com
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

Aytu BioPharma Headlines

No Headlines